p53, p63 and p73
Human gene resources
| Locus | Gene Products | Alternative Name |
|---|---|---|
| TP53 | tumor protein p53 | FLJ92943; LFS1; P53; TRP53 |
| TP63 | tumor protein p63 | AIS; B(p51A); B(p51B); EEC3; KET; LMS; NBP; OFC8; RHS; SHFM4; TP53CP; TP53L; TP73L; p40; p51; p53CP; p63; p73H; p73L |
| TP73 | tumor protein p73 | P73 |
Mouse gne resources
| Locus | Gene Products | Alternative Name |
|---|---|---|
| Trp53 | transformation related protein 53 | Tp53|bbl|bfy|bhy|p44|p53 |
Target genes
Human genevresources
| Locus | Gene Products | Alternative Name |
|---|---|---|
| ABCB1 | ATP-binding cassette, sub-family B (MDR/TAP), member 1 | ABC20; CD243; CLCS; GP170; MDR1; MGC163296; P-GP; PGY1 |
| ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | ABC29; ABCC; DKFZp686N04233; DKFZp781G125; GS-X; MRP; MRP1 |
| AKT1 | v-akt murine thymoma viral oncogene homolog 1 | AKT; MGC99656; PKB; PKB-ALPHA; PRKBA; RAC; RAC-ALPHA |
| AIFM2 | apoptosis-inducing factor, mitochondrion-associated, 2 | AMID; DKFZp686L1298; PRG3; RP11-367H5.2 |
| ANTXR1 | anthrax toxin receptor 1 | ATR; FLJ10601; FLJ11298; FLJ21776; TEM8 |
| APAF1 | apoptotic peptidase activating factor 1 | APAF-1; CED4; DKFZp781B1145 |
| APCS | amyloid P component, serum | MGC88159; PTX2; SAP |
| AQP1 | aquaporin 1 (Colton blood group) | AQP-CHIP; CHIP28; CO; MGC26324 |
| ATR | ataxia telangiectasia and Rad3 related | FRP1; MEC1; SCKL; SCKL1 |
| BAI1 | brain-specific angiogenesis inhibitor 1 | FLJ41988; GDAIF |
| BAI2 | brain-specific angiogenesis inhibitor 2 | BAI2 |
| BAK1 | BCL2-antagonist/killer 1 | BAK; BAK-LIKE; BCL2L7; CDN1; MGC117255; MGC3887 |
| BAX | BCL2-associated X protein | BCL2L4 |
| BBC3 | BCL2 binding component 3 | FLJ42994; JFY-1; JFY1; PUMA |
| BCL2 | B-cell CLL/lymphoma 2 | Bcl-2 |
| BCL2L1 | BCL2-like 1 | BCL-XL/S; BCL2L; BCLX; BCLXL; BCLXS; Bcl-X; DKFZp781P2092; bcl-xL; bcl-xS |
| BCL3 | B-cell CLL/lymphoma 3 | BCL4; D19S37 |
| BIRC5 | baculoviral IAP repeat containing 5 | API4; EPR-1 |
| RNGTT | RNA guanylyltransferase and 5′-phosphatase | CAP1A; DKFZp686J2031; HCE; HCE1; hCAP |
| TP53TG5 | TP53 target 5 | C20orf10; CLG01 |
| CABLES1 | Cdk5 and Abl enzyme substrate 1 | CABL1; CABLES; FLJ35924; HsT2563; IK3-1 |
| CASP1 | caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) | ICE; IL1BC; P45 |
| CAV1 | caveolin 1, caveolae protein, 22kDa | BSCL3; CGL3; MSTP085; VIP21 |
| CCND1 | cyclin D1 | BCL1; D11S287E; PRAD1; U21B31 |
| CHEK1 | CHK1 checkpoint homolog (S. pombe) | CHK1 |
| CHEK2 | CHK2 checkpoint homolog (S. pombe) | CDS1; CHK2; HuCds1; LFS2; PP1425; RAD53 |
| CHUK | conserved helix-loop-helix ubiquitous kinase | IKBKA; IKK-alpha; IKK1; IKKA; NFKBIKA; TCF16 |
| CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | CTNNB; DKFZp686D02253; FLJ25606; FLJ37923 |
| CX3CL1 | chemokine (C-X3-C motif) ligand 1 | ABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1; fractalkine; neurotactin |
| DDB2 | damage-specific DNA binding protein 2, 48kDa | DDBB; FLJ34321; UV-DDB2 |
| DKK1 | dickkopf homolog 1 (Xenopus laevis) | DKK-1; SK |
| DUSP1 | dual specificity phosphatase 1 | CL100; HVH1; MKP-1; MKP1; PTPN10 |
| DUSP12 | dual specificity phosphatase 12 | DUSP1; YVH1 |
| EGFR | epidermal growth factor receptor | ERBB; ERBB1; HER1; PIG61; mENA |
| EGR1 | early growth response 1 | AT225; G0S30; KROX-24; NGFI-A; TIS8; ZIF-268; ZNF225 |
| EPHA2 | EPH receptor A2 | ARCC2; ECK |
| ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1 |
| EZH2 | enhancer of zeste homolog 2 (Drosophila) | ENX-1; ENX1; EZH1; KMT6; KMT6A; MGC9169 |
| FAS | Fas (TNF receptor superfamily, member 6) | ALPS1A; APO-1; APT1; CD95; FAS1; FASTM; TNFRSF6 |
| FDXR | ferredoxin reductase | ADXR |
| GADD45A | growth arrest and DNA-damage-inducible, alpha | DDIT1; GADD45 |
| GML | glycosylphosphatidylinositol anchored molecule like protein | LY6DL |
| HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | C-BAS/HAS; C-H-RAS; C-HA-RAS1; CTLO; H-RASIDX; HAMSV; HRAS1; K-RAS; N-RAS; RASH1 |
| IFI16 | interferon, gamma-inducible protein 16 | IFNGIP1; MGC9466; PYHIN2 |
| IGFBP3 | insulin-like growth factor binding protein 3 | BP-53; IBP3 |
| IL8 | interleukin 8 | CXCL8; GCP-1; GCP1; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1 |
| MKI67 | antigen identified by monoclonal antibody Ki-67 | KIA |
| KLK3 | kallikrein-related peptidase 3 | APS; KLK2A1; PSA; hK3 |
| KLKB1 | kallikrein B, plasma (Fletcher factor) 1 | KLK3; PPK |
| MAD1L1 | MAD1 mitotic arrest deficient-like 1 (yeast) | MAD1; PIG9; TP53I9; TXBP181 |
| MDM2 | Mdm2 p53 binding protein homolog (mouse) | HDMX; MGC5370; MGC71221; hdm2 |
| TNFRSF10C | tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain | CD263; DCR1; DCR1-TNFR; LIT; MGC149501; MGC149502; TRAIL-R3; TRAILR3; TRID |
| MMAB | methylmalonic aciduria (cobalamin deficiency) cblB type | ATR; MGC20496; cblB; cob |
| MMP2 | matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | CLG4; CLG4A; MMP-II; MONA; TBE-1 |
| MSH2 | mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) | COCA1; FCC1; HNPCC; HNPCC1; LCFS2 |
| MYC | v-myc myelocytomatosis viral oncogene homolog (avian) | MRTL; bHLHe39; c-Myc |
| NFATC4 | nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 | NF-ATc4; NFAT3 |
| NFIC | nuclear factor I/C (CCAAT-binding transcription factor) | CTF; CTF5; MGC20153; NF-I; NFI |
| NLRC4 | NLR family, CARD domain containing 4 | CARD12; CLAN; CLAN1; CLANA; CLANB; CLANC; CLAND; CLR2.1; IPAF |
| NME1 | non-metastatic cells 1, protein (NM23A) expressed in | AWD; GAAD; NB; NBS; NDKA; NDPK-A; NDPKA; NM23; NM23-H1 |
| NOL3 | nucleolar protein 3 (apoptosis repressor with CARD domain) | ARC; FLJ35304; MYP; NOP; NOP30 |
| NOS2 | nitric oxide synthase 2, inducible | HEP-NOS; INOS; NOS; NOS2A |
| NTHL1 | nth endonuclease III-like 1 (E. coli) | NTH1; OCTS3 |
| PCNA | proliferating cell nuclear antigen | MGC8367 |
| PIAS3 | protein inhibitor of activated STAT, 3 | FLJ14651; ZMIZ5 |
| PLK1 | polo-like kinase 1 | PLK; STPK13 |
| PLK3 | polo-like kinase 3 | CNK; FNK; PRK |
| PMAIP1 | phorbol-12-myristate-13-acetate-induced protein 1 | APR; NOXA |
| PML | promyelocytic leukemia | MYL; PP8675; RNF71; TRIM19 |
| POLD1 | polymerase (DNA directed), delta 1, catalytic subunit 125kDa | CDC2; POLD |
| PRKAB1 | protein kinase, AMP-activated, beta 1 non-catalytic subunit | AMPK; HAMPKb; MGC17785 |
| PTEN | phosphatase and tensin homolog | 10q23del; BZS; DEC; GLM2; MGC11227; MHAM; MMAC1; PTEN1; TEP1 |
| PTTG1 | pituitary tumor-transforming 1 | EAP1; HPTTG; MGC126883; MGC138276; PTTG; TUTR1 |
| RB1 | retinoblastoma 1 | OSRC; RB; p105-Rb; pRb; pp110 |
| RELA | v-rel reticuloendotheliosis viral oncogene homolog A (avian) | MGC131774; NFKB3; p65 |
| RHOA | ras homolog gene family, member A | ARH12; ARHA; RHO12; RHOH12 |
| RRM2B | ribonucleotide reductase M2 B (TP53 inducible) | DKFZp686M05248; MGC102856; MGC42116; MTDPS8A; MTDPS8B; P53R2 |
| S100B | S100 calcium binding protein B | NEF; S100; S100-B; S100beta |
| SIVA1 | SIVA1, apoptosis-inducing factor | CD27BP; SIVA; Siva-1; Siva-2 |
| SSTR2 | somatostatin receptor 2 | SSTR2 |
| STAT1 | signal transducer and activator of transcription 1, 91kDa | CANDF7; DKFZp686B04100; ISGF-3; STAT91 |
| STAT3 | signal transducer and activator of transcription 3 (acute-phase response factor) | APRF; FLJ20882; HIES; MGC16063 |
| EPCAM | epithelial cell adhesion molecule | DIAR5; EGP-2; EGP314; EGP40; ESA; GA733-2; HNPCC8; KS1/4; KSA; M4S1; MIC18; MK-1; TACSTD1; TROP1 |
| TBXAS1 | thromboxane A synthase 1 (platelet) | BDPLT14; CYP5; CYP5A1; FLJ52771; GHOSAL; THAS; TS; TXAS; TXS |
| TERT | telomerase reverse transcriptase | DKCA2; DKCB4; EST2; TCS1; TP2; TRT; hEST2; hTRT |
| TGFA | transforming growth factor, alpha | TFGA |
| TNFRSF10A | tumor necrosis factor receptor superfamily, member 10a | APO2; CD261; DR4; MGC9365; TRAILR-1; TRAILR1 |
| TNFRSF10B | tumor necrosis factor receptor superfamily, member 10b | CD262; DR5; KILLER; KILLER/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9 |
| TP53 | tumor protein p53 | FLJ92943; LFS1; P53; TRP53 |
| TP53I3 | tumor protein p53 inducible protein 3 | PIG3 |
| TP73 | tumor protein p73 | P73 |
| TP63 | tumor protein p63 | AIS; B(p51A); B(p51B); EEC3; KET; LMS; NBP; OFC8; RHS; SHFM4; TP53CP; TP53L; TP73L; p40; p51; p53CP; p63; p73H; p73L |
| TRIM22 | tripartite motif containing 22 | GPSTAF50; RNF94; STAF50 |
| TYMS | thymidylate synthetase | HST422; MGC88736; TMS; TS |
| UNC5B | unc-5 homolog B (C. elegans) | UNC5H2; p53RDL1 |
| VEGFA | vascular endothelial growth factor A | MGC70609; MVCD1; VEGF; VPF |
| WRN | Werner syndrome, RecQ helicase-like | DKFZp686C2056; RECQ3; RECQL2; RECQL3 |
| XPC | xeroderma pigmentosum, complementation group C | RAD4; XP3; XPCC |
Mouse gene resources
| Locus | Gene Products | Alternative Name |
|---|---|---|
| Abcb1b | ATP-binding cassette, sub-family B (MDR/TAP), member 1B | Abcb1|Mdr1|Mdr1b|Pgy-1|Pgy1|mdr |
| Abcc1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Abcc1a|Abcc1b|MRP|Mdrap|Mrp1 |
| Akt1 | thymoma viral proto-oncogene 1 | Akt|PKB|PKB/Akt|PKBalpha|Rac |
| Cav1 | caveolin 1, caveolae protein | Cav|Cav-1 |
| Cav2 | caveolin 2 | AI447843 |
| Ccnd1 | cyclin D1 | AI327039|Cyl-1|PRAD1|bcl-1|cD1 |
| Chek1 | checkpoint kinase 1 homolog (S. pombe) | C85740|Chk1|rad27 |
| Chek2 | CHK2 checkpoint homolog (S. pombe) | CHK2|Cds1|HUCDS1|Rad53 |
| Egfr | epidermal growth factor receptor | 9030024J15Rik|AI552599|Erbb|Errp|Wa5|wa-2|wa2 |
| Egr1 | early growth response 1 | A530045N19Rik|ETR103|Egr-1|Krox-1|Krox-24|Krox24|NGF1-A|NGFI-A|NGFIA|TIS8|Zenk|Zfp-6|Zif268|egr |
| Erbb2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | Erbb-2|HER-2|HER2|Neu|c-erbB2|c-neu|mKIAA3023 |
| Mdm2 | transformed mouse 3T3 cell double minute 2 | 1700007J15Rik|AA415488|Mdm-2 |
| Myc | myelocytomatosis oncogene | AU016757|Myc2|Niard|Nird|bHLHe39 |
| Plk1 | polo-like kinase 1 (Drosophila) | Plk|STPK13 |
| Rb1 | retinoblastoma 1 | Rb|Rb-1|pRb |
| Stat1 | signal transducer and activator of transcription 1 | 2010005J02Rik|AA408197 |
| Stat3 | signal transducer and activator of transcription 3 | 1110034C02Rik|AW109958|Aprf |
Other resources
| Locus | RDB no. | External DB | Name of Clone | RunningTitle | Type |
|---|---|---|---|---|---|
| APCS | 1820 | Porcine serum amyloid P component | Porcine serum amyloid P component cDNA | DNA clone |
(T.M. Aug, 2008)
go to HeadRenilla Luciferase
| RDB no. | human promoter | HeLa | HepG2 | B16 | MCF-7 | C2C12 | C2C12+DM | LNCaP | LNCaP+dex | Saos-2 | Saos-2serum starvation | 293 | K562 | K562 +TPA | NIH3T3 | p53 over-expression in HepG2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5507 | p53 | – | +++ | |||||||||||||
| 5529 | p73 tumor protein | – | – | – | – | – | + | |||||||||
| 5479 | collagenase type IV | – | +++ | + | – | + | – | – | +++ | |||||||
| 5485 | early growth response protein 1 | – | +++ | ++ | +++ | +++ | ||||||||||
| 5534 | telomerase reverse transcriptase,catalytic subunit | – | + | – | – | – | ||||||||||
| 5910 | proatate-specific antigen/kallikrein 3 | + | – | + | – | + | + | |||||||||
| 5546 | proatate-specific antigen/kallikrein 3 | – | + | – |
Firefly Luciferase
‘Activity’ indicates a value of the fold induction compared with empty vector.
-, less than 2
+, 2 to 5
++, 5 to 10
actual value, more than 10
| Locus symbol | RDB No. | Name of clone | Gene of insert | Other Aliases | Size of inserted DNA | Activity in | |||
|---|---|---|---|---|---|---|---|---|---|
| HeLa | HepG2 | Hep3B | |||||||
| pGL3 Control | pGL3 Control Vector (SV40 promoter) | 372.4 | 159.9 | 226.6 | |||||
| ABCB1 | 7315 | pGL4-phABCB1 | Promoter collection, Human ABCB1 promoter | CLCS; MDR1; P-GP; PGY1; ABC20; CD243; GP170; MGC163296 | 1,219 bp | – | – | + |  |
| AKT1 | 7331 | pGL4-phAKT1 | Promoter collection, Human AKT1 promoter | AKT; PKB; RAC; PRKBA; MGC99656; PKB-ALPHA; RAC-ALPHA | 1,152 bp | – | + | + | |
| ANTXR1 | 7333 | pGL4-phANTXR1 | Promoter collection, Human ANTXR1 promoter | ATR; TEM8; FLJ10601; FLJ11298; FLJ21776 | 1,189 bp | 88.5 | 30.0 | 36.0 | |
| APAF1 | 7316 | pGL4-phAPAF1 | Promoter collection, Human APAF1 promoter | CED4; APAF-1; DKFZp781B1145 | 1,152 bp | 31.0 | 101.0 | 43.0 | |
| APCS | 7317 | pGL4-phAPCS | Promoter collection, Human APCS promoter | SAP; PTX2; MGC88159 | 1,163 bp | + | + | + | |
| ATR | 7334 | pGL4-phATR | Promoter collection, Human ATR promoter | FRP1; MEC1; SCKL; SCKL1 | 1,147 bp | 105.5 | 408.0 | 308.0 | |
| B2M | 7479 | pGL4-phB2M | Promoter collection, Human B2M promoter | 1,420 bp | 339.5 | ++ | + | |
|
| BAI1 | 7401 | pGL4-phBAI1 | Promoter collection, Human BAI1 promoter | GDAIF; FLJ41988 | 1,368 bp | + | + | + | |
| BAK1 | 7318 | pGL4-phBAK1 | Promoter collection, Human BAK1 promoter | BAK; CDN1; BCL2L7; MGC3887; BAK-LIKE; MGC117255 | 1,193 bp | 22.0 | 91.0 | 34.0 | |
| BCL2 | 7567 | pGL4-phBCL2 | Promoter collection, Human BCL2 promoter | Bcl-2 | 1,347 bp | 21.0 | ++ | ++ | |
| BCL2L1 | 7335 | pGL4-phBCL2L1 | Promoter collection, Human BCL2L1 promoter | BCLX; BCL2L; BCLXL; BCLXS; Bcl-X; bcl-xL; bcl-xS; BCL-XL/S; DKFZp781P2092 | 1,214 bp | ++ | 56.0 | 147.0 | |
| BTG2 | 7402 | pGL4-phBTG2 | Promoter collection, Human BTG2 promoter | PC3; TIS21; MGC126063; MGC126064 | 1,356 bp | 285.0 | 1162.0 | 271.0 | |
| CABLES1 | 7337 | pGL4-phCABLES1 | Promoter collection, Human CABLES1 promoter | IK3-1; CABLES; HsT2563; FLJ35924 | 1,222 bp | – | – | + | |
| CASP1 | 7338 | pGL4-phCASP1 | Promoter collection, Human CASP1 promoter | ICE; P45; IL1BC | 1,169 bp | ++ | 16.0 | 20.0 | |
| CAV1 | 7364 | pGL4-phCAV1 | Promoter collection, Human CAV1 promoter | CGL3; BSCL3; VIP21; MSTP085 | 1,309 bp | + | – | + | |
| CCND1 | 7299 | pGL4-phCCND1 | Promoter collection, Human CCND1 promoter | BCL1; PRAD1; U21B31; D11S287E | 1,191 bp | + | 170.0 | ++ | |
| CHEK1 | 7319 | pGL4-phCHEK1 | Promoter collection, Human CHEK1 promoter | CHK1 | 1,208 bp | 83.5 | 31.0 | 110.0 | |
| CHEK2 | 7407 | pGL4-phCHEK2 | Promoter collection, Human CHEK2 promoter | CDS1; CHK2; LFS2; RAD53; HuCds1; PP1425 | 1,312 bp | 57.0 | 80.0 | 34.0 | |
| CHUK | 7383 | pGL4-phCHUK | Promoter collection, Human CHUK promoter | IKK1; IKKA; IKBKA; TCF16; NFKBIKA; IKK-alpha | 1,315 bp | 767.0 | 820.0 | 944.0 | |
| CX3CL1 | 7340 | pGL4-phCX3CL1 | Promoter collection, Human CX3CL1 promoter | NTN; NTT; CXC3; CXC3C; SCYD1; ABCD-3; C3Xkine; fractalkine; neurotactin | 1,236 bp | – | – | + | |
| DKK1 | 7341 | pGL4-phDKK1 | Promoter collection, Human DKK1 promoter | SK; DKK-1 | 1,166 bp | 20.5 | 35.0 | 44.0 | |
| DUSP1 | 7368 | pGL4-phDUSP1 | Promoter collection, Human DUSP1 promoter | HVH1; MKP1; CL100; MKP-1; PTPN10 | 1,165 bp | 173.8 | 176.8 | 1083.5 | |
| DUSP12 | 7384 | pGL4-phDUSP12 | Promoter collection, Human DUSP12 promoter | YVH1; DUSP1 | 1,310 bp | 1593.0 | 1221.0 | 1937.0 | |
| EGFR | 7398 | pGL4-phEGFR | Promoter collection, Human EGFR promoter | ERBB; HER1; mENA; ERBB1; PIG61 | 1,340 bp | 31.0 | 26.0 | 65.0 | |
| EGR1 | 7369 | pGL4-phEGR1 | Promoter collection, Human EGR1 promoter | TIS8; AT225; G0S30; NGFI-A; ZNF225; KROX-24; ZIF-268 | 1,310 bp | 1594.3 | 605.0 | 5730.0 | |
| EPHA2 | 7342 | pGL4-phEPHA2 | Promoter collection, Human EPHA2 promoter | ECK; ARCC2 | 1,163 bp | 26.0 | 152.0 | 81.0 | |
| EZH2 | 7370 | pGL4-phEZH2 | Promoter collection, Human EZH2 promoter | ENX1; EZH1; KMT6; ENX-1; KMT6A; MGC9169 | 1,205 bp | ++ | ++ | 65.5 | |
| FAS | 7349 | pGL4-phFAS | Promoter collection, Human FAS promoter | APT1; CD95; FAS1; APO-1; FASTM; ALPS1A; TNFRSF6 | 1,331 bp | – | + | ++ | |
| FDXR | 7385 | pGL4-phFDXR | Promoter collection, Human FDXR promoter | ADXR | 1,353 bp | 756.0 | 2295.0 | 921.0 | |
| GADD45A | 7320 | pGL4-phGADD45A | Promoter collection, Human GADD45A promoter | DDIT1; GADD45 | 1,225 bp | 214.5 | 675.0 | 313.0 | |
| GML | 7371 | pGL4-phGML | Promoter collection, Human GML promoter | LY6DL | 1,308 bp | – | + | ++ | |
| IFI16 | 7372 | pGL4-phIFI16 | Promoter collection, Human IFI16 promoter | PYHIN2; IFNGIP1; MGC9466 | 1,316 bp | ++ | ++ | 61.5 | |
| IGFBP3 | 7568 | pGL4-phIGFBP3 | Promoter collection, Human IGFBP3 promoter | IBP3; BP-53 | 1,202 bp | 119.0 | 49.5 | 22.2 | |
| IL8 | 7322 | pGL4-phIL8 | Promoter collection, Human IL8 promoter | NAF; GCP1; LECT; LUCT; NAP1; CXCL8; GCP-1; LYNAP; MDNCF; MONAP; NAP-1 | 1,263 bp | 376.5 | 1675.0 | 568.0 | |
| KLK3 | 7324 | pGL4-phKLK3 | Promoter collection, Human KLK3 promoter | APS; PSA; hK3; KLK2A1 | 1,182 bp | + | ++ | ++ | |
| KLKB1 | 7373 | pGL4-phKLKB1 | Promoter collection, Human KLKB1 promoter | PPK; KLK3 | 1,304 bp | ++ | ++ | ++ | |
| MAD1L1 | 7374 | pGL4-phMAD1L1 | Promoter collection, Human MAD1L1 promoter | MAD1; PIG9; TP53I9; TXBP181 | 1,379 bp | 472.0 | 450.0 | 901.0 | |
| MDM2 | 7403 | pGL4-phMDM2 | Promoter collection, Human MDM2 promoter | HDMX; hdm2; MGC5370; MGC71221 | 1,319 bp | ++ | 48.0 | 30.0 | |
| MMP2 | 7314 | pGL4-phMMP2 | Promoter collection, Human MMP2 promoter | CLG4; MONA; CLG4A; TBE-1; MMP-II | 1,160 bp | + | ++ | ++ | |
| MYC | 7325 | pGL4-phMYC | Promoter collection, Human MYC promoter | MRTL; c-Myc; bHLHe39 | 1,267 bp | ++ | ++ | 10.0 | |
| NFATC4 | 7376 | pGL4-phNFATC4 | Promoter collection, Human NFATC4 promoter | NFAT3; NF-ATc4 | 1,315 bp | 33.0 | 19.0 | 47.0 | |
| NFIC | 7399 | pGL4-phNFIC | Promoter collection, Human NFIC promoter | CTF; NFI; CTF5; NF-I; MGC20153 | 1,152 bp | 53.0 | 26.0 | 59.0 | |
| NLRC4 | 7406 | pGL4-phNLRC4 | Promoter collection, Human NLRC4 promoter | CLAN; IPAF; CLAN1; CLANA; CLANB; CLANC; CLAND; CARD12; CLR2.1 | 1,318 bp | – | + | + | |
| NME1 | 7326 | pGL4-phNME1 | Promoter collection, Human NME1 promoter | NB; AWD; NBS; GAAD; NM23; NDPKA; NDPK-A; NM23-H1 | 1,243 bp | 606.5 /Td> | 622.0 | 709.0 | |
| PCNA | 7365 | pGL4-phPCNA | Promoter collection, Human PCNA promoter | MGC8367 | 1,203 bp | 50.0 | 46.8 | 214.0 | |
| PLK1 | 7327 | pGL4-phPLK1 | Promoter collection, Human PLK1 promoter | PLK; STPK13 | 1,221 bp | 11.0 | 24.0 | 15.0 | |
| PML | 7343 | pGL4-phPML | Promoter collection, Human PML promoter | MYL; RNF71; PP8675; TRIM19 | 1,305 bp | 15.5 | 115.0 | 174.0 | |
| POLD1 | 7344 | pGL4-phPOLD1 | Promoter collection, Human POLD1 promoter | CDC2; POLD | 1,308 bp | 200.0 | 145.0 | 238.0 | |
| PRKAB1 | 7328 | pGL4-phPRKAB1 | Promoter collection, Human PRKAB1 promoter | AMPK; HAMPKb; MGC17785 | 1,173 bp | 559.5 | 1031.0 | 702.0 | |
| PTEN | 7400 | pGL4-phPTEN | Promoter collection, Human PTEN promoter | BZS; DEC; GLM2; MHAM; TEP1; MMAC1; PTEN1; 10q23del; MGC11227 | 1,442 bp | + | 75.0 | ++ | |
| PTTG1 | 7329 | pGL4-phPTTG1 | Promoter collection, Human PTTG1 promoter | EAP1; PTTG; HPTTG; TUTR1; MGC126883; MGC138276 | 1,222 bp | 43.5 | 14.0 | 29.0 | |
| RB1 | 7345 | pGL4-phRB1 | Promoter collection, Human RB1 promoter | RB; pRb; OSRC; pp110; p105-Rb | 1,333 bp | 175.0 | 375.0 | 526.0 | |
| RELA | 7366 | pGL4-phRELA | Promoter collection, Human RELA promoter | p65; NFKB3; MGC131774 | 1,149 bp | 136.8 | 73.0 | 399.0 | |
| RHOA | 7404 | pGL4-phRHOA | Promoter collection, Human RHOA promoter | ARHA; ARH12; RHO12; RHOH12 | 1,316 bp | 258.0 | 296.0 | 422.0 | |
| RRM2B | 7346 | pGL4-phRRM2B | Promoter collection, Human RRM2B promoter | P53R2; MGC42116; MGC102856; DKFZp686M05248 | 1,323 bp | ++ | 24.3 | 72.5 | |
| SSTR2 | 7378 | pGL4-phSSTR2 | Promoter collection, Human SSTR2 promoter | 1,320 bp | 48.0 | 57.0 | 116.0 | |
|
| STAT1 | 7405 | pGL4-phSTAT1 | Promoter collection, Human STAT1 promoter | ISGF-3; STAT91; DKFZp686B04100 | 1,313 bp | 46.5 | 198.0 | 103.0 | |
| TBXAS1 | 7347 | pGL4-phTBXAS1 | Promoter collection, Human TBXAS1 promoter | TS; TXS; CYP5; THAS; TXAS; CYP5A1; GHOSAL; FLJ52771 | 1,321 bp | ++ | 46.3 | 25.5 | |
| TERT | 7379 | pGL4-phTERT | Promoter collection, Human TERT promoter | TP2; TRT; EST2; TCS1; hEST2 | 1,341 bp | 76.0 | 27.0 | 90.0 | |
| TGFA | 7348 | pGL4-phTGFA | Promoter collection, Human TGFA promoter | TFGA | 1,305 bp | 23.3 | 36.0 | 124.0 | |
| TNFRSF10B | 7380 | pGL4-phTNFRSF10B | Promoter collection, Human TNFRSF10B promoter | DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5 | 1,305 bp | 40.0 | 65.0 | 228.0 | |
| TP53 | 7330 | pGL4-phTP53 | Promoter collection, Human TP53 promoter | P53; LFS1; TRP53; FLJ92943 | 1,187 bp | 56.0 | 93.0 | 133.0 | |
| TP73 | 7381 | pGL4-phTP73 | Promoter collection, Human TP73 promoter | P73 | 1,332 bp | 10.0 | 14.0 | 41.0 | |
| TRIM22 | 7382 | pGL4-phTRIM22 | Promoter collection, Human TRIM22 promoter | RNF94; STAF50; GPSTAF50 | 1,317 bp | ++ | + | + | |
| VEGFA | 7681 | pGL4-phVEGFA | Promoter collection, Human VEGFA promoter | VPF; VEGF; MVCD1; MGC70609 | 1,305 bp | 125.5 | 27.0 | 20.7 | |
| WRN | 7569 | pGL4-phWRN | Promoter collection, Human WRN promoter | RECQ3; RECQL2; RECQL3; DKFZp686C2056 | 1,320 bp | + | – | – | |
| XPC | 7351 | pGL4-phXPC | Promoter collection, Human XPC promoter | XP3; RAD4; XPCC | 1,301 bp | 141.0 | 341.8 | 482.5 | |
| From Entrez gene on 29.Sep.2010 | |||||||||
Reporter element
| Name of wild-type clone | Running title | Wild-type | Mutant | Map | ||
|---|---|---|---|---|---|---|
| forward | reverse | forward | reverse | |||
| pp53-Box RE-TK hRluc(F) | Reporter construct of p53-Box response element | 5593 | 5656 | 5594 | 5657 | |
(T.M. Dec, 2008)
p53 Status of Cell Line
| Cell line | Origin | Status (link) |
|---|---|---|
| A2780 | Human ovarian tumour cell | p53 status wt, elevated p14(ARF) protein status + p53 gene status [wt] Rb gene status [wt] |
| A375 | p14(ARF) gene status deficient p14(ARF) protein status LTD p53 protein status + p53 gene status [wt] Rb gene status [wt] |
|
| A549 | p53 gene status wt p16(INK4) protein LTD pRb protein + p14(ARF) protein status LTD p14(ARF) gene status + p14(ARF) protein status LTD p53 gene status [wt] Rb gene status [wt] |
|
| ATN-1 | p53 gene status [wt (RCB1440) ] Rb gene status [wt (RCB1440) ] |
|
| BALL-1 | p53 gene status [Asp281Gly (RCB0256) ] Rb gene status [wt (RCB0256) ] |
|
| Bre80 | p14(ARF) gene status + p14(ARF) protein status + p53 gene status wt |
|
| BT-549 | Human breast carcinoma | p16(INK4) protein +++++ p16(INK4) protein + pRb protein LTD p53 gene status – p53 gene status [Arg249Ser] Rb gene status [deletion in coding region] |
| C33A | p53 gene status Mutant, Arg273Cys p53 gene status Mutant, Arg273Cys HPV genome – p16(INK4) protein + pRb protein LTD p53 gene status +/Mutant p14(ARF) gene status + p14(ARF) protein status + p53 gene status [Arg273Cys] Rb gene status [mutation in an intron] |
|
| CHP-126 | p53 gene status [wt (RCB0486) ] Rb gene status [wt (RCB0486) ] |
|
| CHP-134 | p53 gene status [wt (RCB0487) ] Rb gene status [wt (RCB0487) ] |
|
| COLO 679 | p53 gene status [wt (RCB0989) ] Rb gene status [wt (RCB0989) ] |
|
| CTB-1 | p53 gene status [wt (RCB1316) ] Rb gene status [wt (RCB1316) ] |
|
| CW-2 | p53 gene status [wt (RCB0778) ] Rb gene status [wt (RCB0778) ] |
|
| ECC10 | p53 gene status [wt (RCB0983) ] Rb gene status [Gln685stop (RCB0983) ] |
|
| ECC12 | p53 gene status [Val216Met (RCB1009) ] Rb gene status [deletion (RCB1009) ] |
|
| ECC4 | p53 gene status [deletion (RCB0982) ] Rb gene status [Arg661Trp (RCB0982) ] |
|
| EC-GI-10 | p53 gene status [Tyr234Cys, Arg273Leu (RCB0774) ] Rb gene status [wt (RCB0774) ] |
|
| EoL-1 cell | p53 gene status [wt (RCB0641) ] Rb gene status [wt (RCB0641) ] |
|
| ETK-1 | p53 gene status [Arg175His (RCB1289) ] Rb gene status [wt (RCB1289) ] |
|
| G401 | p53 status wt p14(ARF) protein status LTD p53 gene status [wt] Rb gene status [wt] |
|
| GCIY | p53 gene status [Glu11Gln, His179Gln (RCB0555) ] Rb gene status [wt (RCB0555) ] |
|
| GI-1 | p53 gene status [Cys275Tyr (RCB0763) ] Rb gene status [Arg552stop (RCB0763) ] |
|
| GM 639 DM | p14(ARF) gene status + p14(ARF) protein status + p53 gene status wt/LT |
|
| GM 847 DM | p14(ARF) gene status + p14(ARF) protein status + p53 gene status wt/LT |
|
| GOTO-P3 | p53 gene status [wt (RCB0721) ] Rb gene status [wt (RCB0721) ] |
|
| GR-ST | p53 gene status [Met246Thr (RCB1182) ] Rb gene status [mutation in an intron (RCB1182) ] |
|
| H1299 | p53 gene status Null, deletion p14(ARF) protein status +++ p53 gene status Null p14(ARF) gene status + p14(ARF) protein status ++ |
|
| HAL-01 | p53 gene status [wt (RCB0540) ] Rb gene status [wt (RCB0540) ] |
|
| HCE-T | p53 gene status [wt (RCB1384) ] Rb gene status [wt (RCB1384) ] |
|
| HCT116 | p53 gene status wt p16(INK4) protein LTD pRb protein + p53 status wt p14(ARF) protein status LTD p53 protein status + p53 gene status [wt] Rb gene status [wt] |
|
| HCT116 TP53 -/- | p53 status KO p14(ARF) protein status LTD |
|
| HDF | p14(ARF) gene status + p14(ARF) protein status LTD p53 gene status wt |
|
| HEK293 | Human embryonic kidney | p53 gene status wt/E1b55k pRb genotype +/E1A p16(INK4) protein + pRb protein +/E1A p16(INK4) protein ++++ p14(ARF) gene status + p14(ARF) protein status + p53 gene status wt/E1b55k |
| HeLa | Human cervical carcinoma | HPV genome HPV-18/+ p53 gene status wt/E6 pRb genotype +/E7 p16(INK4) protein ++++ p14(ARF) gene status + p14(ARF) protein status ++ p53 gene status wt/E6 |
| H-EMC-SS | p53 gene status [wt (RCB0508) ] Rb gene status [wt (RCB0508) ] |
|
| Hep3B | Human hepatoma | p53 gene status partial deletion p53 protein status LTD P16 genotype + p16(INK4) protein + pRb protein LTD p53 gene status -/deficient |
| HepG2 | Human hepatoma | p53 gene status wt (Southern blott) p53 protein status + P16 genotype + p16(INK4) protein + pRb protein + p14(ARF) gene status + p14(ARF) protein status LTD |
| HGC-27 | p53 gene status [flameshift after Pro153 (RCB0500) ] Rb gene status [wt (RCB0500) ] |
|
| HMV-II | p53 gene status [Asn268Ile (RCB0777) ] Rb gene status [wt (RCB0777) ] |
|
| HT29 | p53 gene status Mutant, Arg273His p16(INK4) protein LTD pRb protein + p16(INK4) protein LTD p53 protein status + pRb protein + p14(ARF) protein status + p14(ARF) protein status ++ p53 gene status [Arg273His] Rb gene status [wt] |
|
| HTC/C3 | p53 gene status [Pro152Leu (RCB0452) ] Rb gene status [wt (RCB0452) ] |
|
| HuH-7 | Human hepatoma | p53 gene status Mutant, Tyr220Cys p16(INK4) protein LTD p53 protein status +, truncated pRb protein + p53 gene status [Tyr220Cys (RCB1366) ] Rb gene status [wt (RCB1366) ] |
| IA-LM | p53 gene status [wt (RCB0554) ] Rb gene status [wt (RCB0554) ] |
|
| IIICF/c | p14(ARF) gene status – p14(ARF) protein status LTD p53 gene status Null |
|
| J82 | p14(ARF) gene status + p14(ARF) protein status ++ p53 gene status Mutant p53 gene status [Lys320Asn, deletion in coding region] Rb gene status [mutation in an intron] |
|
| KGN | p53 gene status [wt (RCB1154) ] Rb gene status [wt (RCB1154) ] |
|
| KP4 | p53 gene status [wt (RCB1005) ] Rb gene status [wt (RCB1005) ] |
|
| KU812 | p53 gene status p53 gene status [wt (RCB0495) ] Rb gene status [wt (RCB0495) ] |
|
| LC-1F | p53 gene status [Met237Ile (RCB0439) ] Rb gene status [wt (RCB0439) ] |
|
| LC-2/ad | p53 gene status [deletion in coding region (RCB0440) ] Rb gene status [wt (RCB0440) ] |
|
| LOVO | Human colon carcinoma | p16(INK4) protein LTD p53 protein status LTD pRb protein + p16(INK4) protein LTD p53 protein status LTD pRb protein + p53 gene status [wt] Rb gene status [wt] |
| LS 174 T | Human colon carcinoma | p16(INK4) protein LTD pRb protein + p53 gene status wt p53 gene status [wt] Rb gene status [wt] |
| Lu-134-A | p53 gene status [Pro278Leu (RCB0466) ] Rb gene status [Try75stop (RCB0466) ] |
|
| Lu-135 | p53 gene status [Gly244Cys (RCB0468) ] Rb gene status [flame shift after Arg661 (RCB0468) ] |
|
| Lu-139 | p53 gene status [Val157Phe (RCB0469) ] Rb gene status [flame shift after Gly617 (RCB0469) ] |
|
| Lu-165 | p53 gene status [deletion in an intron (RCB1184) ] Rb gene status [flame shift after Val157 (RCB1184) ] |
|
| MCF-7 | Human breast carcinoma | p16(INK4) protein LTD pRb protein + p16(INK4) protein LTD pRb protein + p14(ARF) protein status LTD p53 protein status + p53 status +/wt p53 gene status wt p53 gene status [wt] Rb gene status [wt] |
| MD468 | p53 gene status +/Mutant | |
| MDA-MB-453 | p53 gene status [wt (RCB1192) ] Rb gene status [wt (RCB1192) ] |
|
| MFH-ino | p53 gene status [wt (RCB0749) ] Rb gene status [wt (RCB0749) ] |
|
| MKN28 | p53 gene status [Ile251Leu (RCB1000) ] Rb gene status [wt (RCB1000) ] |
|
| MKN45 | p53 gene status Arg110Cys p53 gene status [wt (RCB1001) ] Rb gene status [wt (RCB1001) ] |
|
| MMAc-SF | p53 gene status [wt (RCB1200) ] Rb gene status [wt (RCB1200) ] |
|
| NB16 | p53 gene status [Arg175His (RCB0478) ] Rb gene status [wt (RCB0478) ] |
|
| NB69 | p53 gene status [wt (RCB0480) ] Rb gene status [wt (RCB0480) ] |
|
| NBsusSR | p53 gene status [wt (RCB0803) ] Rb gene status [wt (RCB0803) ] |
|
| NEC8 | p53 gene status [wt (RCB0489) ] Rb gene status [wt (RCB0489) ] |
|
| NOS-1 | p53 gene status [Arg273His (RCB1032) ] Rb gene status [wt (RCB1032) ] |
|
| OCUB-M | p53 gene status [Gly244Ser (RCB0881) ] Rb gene status [flame shift after Ile42 (RCB0881) ] |
|
| OMC-1 | p53 gene status [wt (RCB0753) ] Rb gene status [wt (RCB0753) ] |
|
| OS-RC-2 | p53 gene status [wt (RCB0735) ] Rb gene status [wt (RCB0735) ] |
|
| PC-14 | p53 gene status [Arg248Gln (RCB0446) ] Rb gene status [wt (RCB0446) ] |
|
| RCC10RGB | p53 gene status [wt (RCB1151) ] Rb gene status [wt (RCB1151) ] |
|
| RKO | p14(ARF) gene status + p14(ARF) protein status LTD p53 gene status wt p53 gene status [wt] Rb gene status [wt] |
|
| RKO p53.13 | p14(ARF) gene status + p14(ARF) protein status LTD p53 gene status wt/DN |
|
| Saos 2 | p14(ARF) gene status + p14(ARF) protein status + p14(ARF) protein status + p16(INK4) protein +/- p53 gene status Null p53 gene status deletion coding region p53 protein status LTD pRb protein +/truncated p53 gene status [wt] Rb gene status [deletion in coding region] |
|
| T98G | p14(ARF) protein status LTD pRb protein + p14(ARF) gene status – p14(ARF) protein status LTD p53 gene status Mutant p53 gene status [Met237Ile] Rb gene status [wt] |
|
| TC-YIK | p53 gene status [deletion in coding region (RCB0443) ] Rb gene status [wt (RCB0443) ] |
|
| TGBC11TKB | p53 gene status [Arg273Cys, flame shift after Lys382 (RCB1148) ] Rb gene status [wt (RCB1148) ] |
|
| TGBC1TKB | p53 gene status [flame shift after Cys176 (RCB1129) ] Rb gene status [wt (RCB1129) ] |
|
| TGBC24TKB | p53 gene status [flame shift after Cys242 (RCB1196) ] Rb gene status [wt (RCB1196) ] |
|
| TIG3 | p14(ARF) protein status LTD | |
| U2OS | osteosarcoma | p53 gene status wt p53 protein status + p16(INK4) protein LTD p14(ARF) protein status LTD p53 gene status wt p14(ARF) protein status LTD p14(ARF) gene status + p14(ARF) protein status LTD p53 gene status [wt] Rb gene status [wt] |
| U373 | glioblastoma | p53 gene status negative, codon 273 mutation |
| U87 | glioblastoma | p53 gene status wt p14(ARF) protein status LTD |
| WI-38 | normal fibloblast | p16(INK4) protein + p16(INK4) protein + pRb protein + |
LTD, less than detection.
Data in [ ], from Cancer Cell Line Project, COSMIC, Wellcome Trust Sanger Institute. (http://www.sanger.ac.uk/genetics/CGP/cosmic/)
Reference
- Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A. 87 (5): 1973-1977, 1990.
- Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282 (5393): 1497-501.
- Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6 (5): 873-875, 1991.
- Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 1990 Nov;10(11):5772-5781.
- Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M, Royds J, Braithwaite AW. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol. 2002 Dec;76(24):12483-90.
- Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72 (12): 9479-9490, 1998.
- GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59.74.
- Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (18): 4855-4878, 1994.
- Higashi, H., I. Suzuki-Takahashi, E. Yoshida, S. Nishimura, and M. Kitagawa. 1997. Expression of p16INK4a suppresses the unbounded and anchorage- independent growth of a glioblastoma cell line that lacks p16INK4a. Biochem. Biophys. Res. Commun. 231:743.750.
- Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, Harris CC. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 4 (5): 987-992, 1993.
- Huschtscha, L. I., J. R. Noble, A. A. Neumann, E. L. Moy, P. Barry, J. R. Melki, S. J. Clark, and R. R. Reddel. 1998. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 58:3508-3512.
- Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog. 19 (4): 243-253, 1997.
- Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A. 90 (9): 3988-3992, 1993.
- Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51 (15): 4090-4096, 1991.
- Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A. 84 (21): 7716-7719, 1987.
- Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D’Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7 (1): 171-180, 1992.
- OKAMOTO, A., DEMETRICK, D.J., SPILLARE, E.A., HAGIWARA, K., HUSSAIN, S.P., BENNETT, W.P., FORRESTER, K., GERWIN, B., SERRANO, M., and BEACH, D.H. (1994). Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. U.S.A. 91, 11045.11049.
- Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000 Oct;6(10):1128-1133.
- Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 87 (19): 7555-7559, 1990.
- Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, Englezou A, Warneford SG, Dalla-Pozza L, Reddel RR. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol. 1995 Sep;15(9):4745-4753.
- Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72 (12): 9470-9478, 1998.
- Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 3 (3): 313-319, 1997.
- Scheffner M, Mnger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A. 88 (13): 5523-5527, 1991.
- SCHNEIDER-GADICKE, A., and SCHWARZ, E. (1986). Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 5, 2285.2292.
- Steegenga WT, Riteco N, Bos JL. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells. Oncogene 18 (36): 5032-5043, 1999.
- Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.EMBO J. 1998 Sep 1;17(17):5001-5014.
- Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 54 (22): 5816-5820, 1994.
- Tominaga O, Nita ME, Nagawa H, Fujii S, Tsuruo T, Muto T. Expressions of cell cycle regulators in human colorectal cancer cell lines. Jpn J Cancer Res. 88 (9): 855-860, 1997.
- Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73 (3): 2074-2083, 1999.
- Ullrich SJ, Sakaguchi K, Lees-Miller SP, Fiscella M, Mercer WE, Anderson CW, Appella E. Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc Natl Acad Sci U S A. 90 (13): 5954-5958, 1993.
- Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55 (22): 5187-5190, 1995.
- Whitaker NJ, Bryan TM, Bonnefin P, Chang AC, Musgrove EA, Braithwaite AW, Reddel RR. Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene 11 (5): 971-976, 1995.
(T.M. Aug, 2008)
p53 Mutant
Amino acid sequence of human T53 (NCBI NM_000546.4)
| 1 | MEEPQSDPSV | EPPLSQETFS | DLWKLLPENN | VLSPLPSQAM | DDLMLSPDDI | 50 |
| 51 | EQWFTEDPGP | DEAPRMPEAA | PPVAPAPAAP | TPAAPAPAPS | WPLSSSVPSQ | 100 |
| 101 | KTYQGSYGFR | LGFLHSGTAK | SVTCTYSPAL | NKMFCQLAKT | CPVQLWVDST | 150 |
| 151 | PPPGTRVRAM | AIYKQSQHMT | EVVRRCPHHE | RCSDSDGLAP | PQHLIRVEGN | 200 |
| 201 | LRVEYLDDRN | TFRHSVVVPY | EPPEVGSDCT | TIHYNYMCNS | SCMGGMNRRP | 250 |
| 251 | ILTIITLEDS | SGNLLGRNSF | EVRVCACPGR | DRRTEEENLR | KKGEPHHELP | 300 |
| 301 | PGSTKRALPN | NTSSSPQPKK | KPLDGEYFTL | QIRGRERFEM | FRELNEALEL | 350 |
| 351 | KDAQAGKEPG | GSRAHSSHLK | SKKGQSTSRH | KKLMFKTEGP | DSD | 393 |
Dominant Negative and Recessive p53 Mutants
| codon no. | wt AA | mut AA | Transdominance | Recessive mutation |
|---|---|---|---|---|
| 53 | Cys | Stop | no | |
| 68 | Glu | Gly | no | |
| 83 | Ala | Glu | no | |
| 86 | Ala | Glu | no | |
| 86 | Ala | Thr | no | |
| 91 | Trp | Stop | no | |
| 91 | Trp | Stop | no | |
| 98 | Pro | His | no | |
| 98 | Pro | Leu | no | |
| 98 | Pro | Ser | no | |
| 99 | Ser | Phe | no | |
| 99 | Ser | Tyr | no | |
| 108 | Gly | Ser | no | |
| 110 | Arg | Cys | mt | |
| 110 | Arg | Leu | mt | |
| 111 | Leu | Arg | no | |
| 115 | His | Tyr | no | |
| 117 | Gly | Glu | no | |
| 119 | Ala | Val | no | |
| 124 | Cys | Arg | no | |
| 125 | TYSPALNKM | TM | no | |
| 126 | Tyr | Asp | no | |
| 126 | Tyr | Ser | no | |
| 127 | Ser | Pro | Weak | |
| 127 | Ser | Tyr | no | |
| 132 | Lys | Arg | mt | |
| 132 | Lys | Asn | Weak | |
| 133 | Met | Arg | no | |
| 135 | Cys | Phe | Weak | |
| 135 | Cys | Phe | no | |
| 135 | Cys | Trp | no | |
| 138 | Ala | Lys | no | |
| 139 | Lys | Asn | no | |
| 139 | Lys | Glu | no | |
| 143 | Val | Ala | mt | |
| 144 | Gln | Pro | no | |
| 146 | Trp | Stop | no | |
| 150 | Thr | Ile | no | |
| 151 | Pro | Arg | Weak | |
| 151 | Pro | His | Weak | |
| 151 | Pro | His | no | |
| 151 | Pro | Ser | no | |
| 152 | Pro | Leu | no | |
| 152 | Pro | Leu | no | |
| 152 | Pro | Thr | no | |
| 155 | Thr | Ile | no | |
| 156 | Arg | His | Yes | |
| 156 | Arg | Pro | no | |
| 158 | Arg | Cys | no | |
| 158 | Arg | Gly | no | |
| 158 | Arg | His | no | |
| 158 | Arg | His | no | |
| 158 | Arg | Pro | Weak | |
| 161 | Ala | Asp | no | |
| 161 | Ala | Gly | no | |
| 161 | Ala | Val | no | |
| 162 | Ile | Phe | no | |
| 163 | Tyr | Asn | no | |
| 163 | Tyr | Cys | no | |
| 163 | Tyr | His | no | |
| 167 | Gln | Arg | no | |
| 167 | Gln | Stop | no | |
| 168 | His | Arg | no | |
| 168 | His | Gln | no | |
| 168 | His | Tyr | Yes | |
| 170 | Thr | Arg | no | |
| 173 | Val | Gly | no | |
| 173 | Val | Leu | no | |
| 173 | Val | Met | no | |
| 175 | Arg | His | Weak | |
| 175 | Arg | His | Yes | |
| 175 | Arg | His | Yes | |
| 175 | RCPHHERCSD | RCSD | Weak | |
| 176 | Cys | Arg | Weak | |
| 176 | Cys | Phe | no | |
| 176 | Cys | Ser | no | |
| 176 | Cys | Tyr | no | |
| 177 | Pro | His | Yes | |
| 177 | Pro | His | Yes | |
| 177 | Pro | Phe | Yes | |
| 177 | Pro | Ser | Yes | |
| 177 | Pro | Ser | Yes | |
| 178 | His | Pro | Yes | |
| 179 | His | Arg | Yes | |
| 179 | His | Asn | Yes | mt |
| 179 | His | Pro | mt | |
| 179 | His | Tyr | Yes | |
| 180 | Glu | Lys | no | |
| 181 | Arg | Cys | no | |
| 181 | Arg | Gly | no | |
| 181 | Arg | His | no | |
| 181 | Arg | Leu | no | |
| 181 | Arg | Pro | Yes | |
| 190 | Pro | His | no | |
| 193 | His | Leu | no | |
| 196 | Arg | Gln | no | |
| 196 | Arg | Stop | no | |
| 197 | Val | Leu | no | |
| 199 | Gly | Arg | no | |
| 201 | Leu | Stop | no | |
| 202 | Arg | Ser | no | |
| 213 | Arg | Gln | no | |
| 213 | Arg | Stop | no | |
| 213 | Arg | Stop | no | |
| 213 | Arg | Stop | no | |
| 214 | His | Arg | mt | |
| 215 | Ser | Cys | no | |
| 216 | ValValVal | ValVal | Weak | |
| 219 | Pro | His | no | |
| 219 | Pro | Leu | no | |
| 220 | Tyr | Cys | no | mt |
| 220 | Tyr | His | no | |
| 220 | Tyr | His | no | |
| 224 | Glu | Lys | no | |
| 227 | Ser | Cys | no | |
| 228 | Asp | Val | no | |
| 230 | Thr | Ser | no | |
| 234 | Tyr | Cys | mt | |
| 234 | Tyr | His | no | |
| 236 | Tyr | Asp | Weak | |
| 236 | Tyr | Ser | no | |
| 239 | Asn | Ser | Yes | |
| 240 | SerSerCysMet | Val | Yes | |
| 241 | Ser | Ala | Yes | |
| 241 | Ser | Phe | Yes | |
| 241 | Ser | Phe | Yes | mt |
| 241 | Ser | Thr | Yes | |
| 242 | Cys | Phe | Weak | |
| 242 | Cys | Tyr | Yes | |
| 242 | Cys | Tyr | Yes | |
| 244 | Gly | Ala | mt | |
| 244 | Gly | Asp | Yes | |
| 244 | Gly | Asp | Yes | |
| 244 | Gly | Ser | Yes | |
| 244 | Gly | Ser | Yes | |
| 245 | Gly | Arg | Yes | |
| 245 | Gly | Asp | Yes | |
| 245 | Gly | Asp | Yes | |
| 245 | Gly | Asp | Yes | |
| 245 | Gly | Asp | Yes | |
| 245 | Gly | Ser | Yes | |
| 245 | Gly | Ser | Yes | |
| 245 | Gly | Ser | Yes | |
| 245 | Gly | Val | no | |
| 246 | Met | Arg | Yes | |
| 246 | Met | Arg | Yes | |
| 246 | Met | Ile | Weak | |
| 246 | Met | Leu | Yes | |
| 248 | Arg | Gln | Yes | |
| 248 | Arg | Gln | Yes | mt |
| 248 | Arg | Gly | mt | |
| 248 | Arg | Leu | mt | |
| 248 | Arg | Trp | Yes | |
| 248 | Arg | Trp | Yes | |
| 248 | Arg | Trp | Yes | |
| 249 | Arg | Ser | Yes | |
| 249 | Arg | Ser | Yes | mt |
| 250 | Pro | Leu | no | |
| 250 | PILTIIT | PIIT | Weak | |
| 251 | Ile | Leu | mt | |
| 252 | Leu | Ile | Weak | |
| 252 | Leu | Phe | no | |
| 257 | Leu | Gln | Weak | |
| 257 | Leu | Pro | Weak | |
| 257 | Leu | Pro | Yes | |
| 257 | Leu | Pro | no | |
| 258 | Glu | Lys | no | |
| 259 | Asp | Asn | no | |
| 259 | Asp | Tyr | Weak | |
| 259 | Asp | Val | no | |
| 262 | Gly | Asp | no | |
| 262 | Gly | Cys | no | |
| 264 | Leu | Arg | no | |
| 265 | Leu | Pro | Weak | |
| 266 | Gly | Arg | no | |
| 266 | Gly | Arg | no | |
| 266 | Gly | Glu | no | |
| 266 | Gly | Glu | no | |
| 266 | Gly | Val | no | |
| 270 | Phe | Ser | no | |
| 272 | Val | Gly | no | |
| 272 | Val | Leu | mt | |
| 272 | Val | Met | mt | |
| 273 | Arg | Cys | Yes | |
| 273 | Arg | Cys | Yes | |
| 273 | Arg | Cys | Yes | |
| 273 | Arg | His | Yes | mt |
| 273 | Arg | His | Yes | |
| 273 | Arg | Leu | Yes | |
| 273 | Arg | Pro | Weak | |
| 274 | Val | Phe | Yes | |
| 275 | Cys | Phe | no | |
| 275 | Cys | Tyr | no | |
| 276 | Ala | Val | no | |
| 277 | Cys | Tyr | Yes | |
| 277 | Cys | Tyr | no | |
| 278 | Pro | His | Weak | |
| 278 | Pro | Ser | Weak | |
| 278 | Pro | Ser | no | |
| 279 | Gly | Arg | Yes | |
| 279 | Gly | Glu | Yes | |
| 279 | Gly | Glu | Yes | |
| 279 | Gly | Glu | Yes | |
| 279 | Gly | Val | Yes | |
| 280 | Arg | Gly | Yes | |
| 280 | Arg | Ile | Yes | |
| 280 | Arg | Ser | Yes | |
| 280 | Arg | Ser | Yes | |
| 280 | Arg | Thr | Yes | |
| 281 | Asp | Asn | Yes | |
| 281 | Asp | Asn | Yes | |
| 281 | Asp | Glu | Yes | |
| 281 | Asp | Gly | Yes | |
| 281 | Asp | Tyr | Yes | |
| 281 | Asp | Tyr | Yes | mt |
| 282 | Arg | Gln | no | |
| 282 | Arg | Trp | no | mt |
| 283 | Arg | His | no | |
| 285 | Glu | Lys | mt | |
| 286 | Glu | Gly | no | |
| 286 | Giu | Lys | no | |
| 298 | Glu | Stop | mt | |
| 305 | Lys | Asn | no | |
| 305 | Lys | Met | no | |
| 306 | Arg | Glu | no | |
| 306 | Arg | Stop | no | |
| 306 | Arg | Stop | no | |
| 308 | Leu | Met | no | |
| 323 | Leu | Pro | no | |
| 327 | Tyr | Stop | no | |
| 331 | Gln | Stop | no | |
| 331 | Gln | Stop | no | |
| 337 | Arg | Pro | no | |
| 337 | Arg | Ser | no | |
| 338 | FEMFRELNEA | FA | no | |
| 342 | Arg | Stop | no | |
| 347 | Ala | Gly | no |
Reference
- Brachmann RK, Vidal M, Boeke JD. Dominant-negative p53 mutations selected in yeast hit cancer hot spots.Proc Natl Acad Sci U S A. 1996; 93: 4091-4095.
- Inga A, Monti P, Fronza G, Darden T, Resnick MA. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene. 2001; 20: 501-513.
- Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog. 19 (4): 243-253, 1997.
- Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada J, Asaka M, Moriuchi T. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res. 1999; 59: 4765-4769.
- Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, Resnick MA, Fronza G. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene. 2002; 21: 1641-1648.
- Sakuragi N, Watari H, Ebina Y, Yamamoto R, Steiner E, Koelbl H, Yano M, Tada M, Moriuchi T. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer. 2005; 116: 514-519.
(T.M. Jan, 2009)
(GSB0020e, T.M. 2006.02.13)
2023.06.08
